Skip to content
value.today

eyeBrain Medical, Inc.

Formerly Yelroc Neuro, Inc.

Total raised
$112 M
5 rounds on record
Latest round
$68 M
Sep 2022
First round on record
Oct 2014
Today
Private
No later event on record

Funding rounds

5 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of eyeBrain Medical, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Sep 2022$68 MNo. 5$50 to $250 million

eyeBrain Medical, Inc.: Raise no. 5, Sep 2022

Investors in this round

31 investors had bought by the notice of Sep 13, 2022: 31 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$68 M of $68 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Aric Plumley · Executive Officer
  • Danny Perales · Executive Officer
  • Davis Corley · Executive Officer, Director
  • Pierre Bertrand · Executive Officer
  • Akhilesh Pathipati · Director
  • Das Narayandas · Director
  • Eric Bednarski · Director
  • J. Andy Corley · Director
  • Steve Kirby · Director
  • Tom Finzi · Director
  • William Link · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Total amount sold includes $52,011,674.81 of new cash and $15,631,127.67 of conversion of debt.”

Signed by Pierre Bertrand, Ceo. Source: SEC Form D, newest notice filed Sep 13, 2022. Read the notice at the SEC.

equitySEC
Jul 2019$24 MNo. 4$10 to $50 million

eyeBrain Medical, Inc.: Raise no. 4, Jul 2019

Investors in this round

24 investors had bought by the notice of Mar 12, 2020: 24 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$24 M of $24 M offered; $0 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Daniel Perales · Executive Officer
  • Davis Corley · Executive Officer, Director
  • J. Andy Corley · Executive Officer, Director
  • Dean Butler · Director
  • John T. Tullis · Director
  • Steve T. Kirby · Director
  • Tom Frinzi · Director
  • William T. Link · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Davis Corley, President. Source: SEC Form D and 2 amendments, newest notice filed Mar 12, 2020. Read the notice at the SEC.

equitySEC
Nov 2017$13 MNo. 3$10 to $50 million

eyeBrain Medical, Inc.: Raise no. 3, Nov 2017

Investors in this round

35 investors had bought by the notice of Dec 27, 2017: 35 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$13 M of $14 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Daniel Perales · Executive Officer
  • Davis Corley · Executive Officer, Director
  • J. Andy Corley · Executive Officer, Director
  • Dean Butler · Director
  • Steve T. Kirby · Director
  • Tom Frinzi · Director
  • William T. Link · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “$1,521,917.80 in conversion of promissory notes; $11,599,987.97 in new money.”

Signed by Davis Corley, President. Source: SEC Form D and 1 amendment, newest notice filed Dec 27, 2017. Read the notice at the SEC.

equitySEC
Dec 2015$6 MNo. 2$2 to $10 million

eyeBrain Medical, Inc.: Raise no. 2, Dec 2015

Investors in this round

21 investors had bought by the notice of Dec 28, 2015: 21 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$6 M of $6 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Davis Corley · Executive Officer

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “$5,550,001.63 in new money; $490,479.64 cancellation of debt”

Signed by Davis Corley, President. Source: SEC Form D, newest notice filed Dec 28, 2015. Read the notice at the SEC.

equitySEC
Oct 2014$1 MNo. 1Under $2 million

eyeBrain Medical, Inc.: Raise no. 1, Oct 2014

Investors in this round

1 investor had bought by the notice of Nov 4, 2014: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $1 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Davis Andy Corley · Executive Officer, Promoter
  • J. Andy Corley · Executive Officer, Director, Promoter
  • Jeffrey Andy Krall · Promoter · Mr. Krall is the manager of Legacy Optics, LLC, a promoter of the Issuer.

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “The Issuer will use proceeds of the offering for general working capital purposes including salary payments to its executive officers in the ordinary course of business.”

Signed by Davis Corley, Chief Financial Officer and Secretary. Source: SEC Form D, newest notice filed Nov 4, 2014. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • eyeBrain Medical, Inc. chose not to state its revenue in its newest notice of a funding round (Sep 2022).

    SEC Form D · Sep 2022

  • The industry group it chose in its notices: Other Technology.

    SEC Form D · Sep 2022

That is all the official record says: eyeBrain Medical, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of eyeBrain Medical, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 5 rounds above had up to 35 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by eyeBrain Medical, Inc.
NameRoleNamed in
Aric PlumleyExecutive officerSep 2022
Danny PeralesExecutive officerSep 2022
Davis CorleyExecutive officerSep 2022
Pierre BertrandExecutive officerSep 2022
Daniel PeralesExecutive officerMar 2020
J. Andy CorleyExecutive officerMar 2020
Davis Andy CorleyExecutive officerNov 2014
Akhilesh PathipatiDirectorSep 2022
Das NarayandasDirectorSep 2022
Davis CorleyDirectorSep 2022
Eric BednarskiDirectorSep 2022
J. Andy CorleyDirectorSep 2022
Steve KirbyDirectorSep 2022
Tom FinziDirectorSep 2022
William LinkDirectorSep 2022
Dean ButlerDirectorMar 2020
John T. TullisDirectorMar 2020
Steve T. KirbyDirectorMar 2020
Tom FrinziDirectorMar 2020
William T. LinkDirectorMar 2020
Davis Andy CorleyPromoterNov 2014
J. Andy CorleyPromoterNov 2014
Jeffrey Andy KrallMr. Krall is the manager of Legacy Optics, LLC, a promoter of the Issuer.Nov 2014